Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in major bleeding compared with placebo or no treatment (low certainty).
1 finding from 1 review
Major bleeding · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in major bleeding compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Major bleeding · people with ST of the leg
1 finding from 1 review
Major bleeding · people with ST of the leg
Fondaparinux showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · people with superficial thrombophlebitis of the leg
1 finding from 1 review
Major bleeding · people with ST of the leg
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to higher major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleedinge · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in major bleedinge compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people with distal DVT
Anticoagulant showed no clear difference in major bleeding ( compared with no intervention or placebo (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingh compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with distal DVT
Anticoagulant leads to higher clinically relevant non‐major bleeding ( compared with no intervention or placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Bleeding ‐ major (bleeding requiring transfusion) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ major (bleeding requiring transfusion) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review